SP1 and plasma cell myeloma: The fact that it has been shown that bortezomib also leads to transcriptional downregulation of Sp1 (another transcription factor involved in the regulation of KIT39) as well as Notch in multiple myeloma and acute lymphocytic leukemia strengthens our hypothesis40,41.